Stockscreener 앱 받기
23.80
3.16%
0.73
시간 외 거래:
23.33
-0.47
-1.97%
Catalyst Pharmaceuticals Inc 주식(CPRX)의 최신 뉴스
NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data - TradingView
Aug Technicals: Can Catalyst Pharmaceuticals Inc stock outperform in a bear market2026 Price Targets & Fast Exit/Entry Strategy Plans - baoquankhu1.vn
Retail Trends: Does Catalyst Pharmaceuticals Inc align with a passive investing strategy2026 Market WrapUp & Low Drawdown Momentum Ideas - baoquankhu1.vn
Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug - TradingView
INSM Stock Gains After Arikayce Hits Goal in Label Expansion Study - TradingView
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
GSK's Risvutatug Rezetecan Gets Japan Orphan Drug Tag for Lung Cancer - TradingView
CPRX Technical Analysis | Trend, Signals & Chart Patterns | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
Will Catalyst Pharmaceuticals Inc benefit from government policyWeekly Loss Report & AI Forecast Swing Trade Picks - baoquankhu1.vn
Is Catalyst Pharmaceuticals Inc a momentum stock2026 Growth vs Value & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Momentum Cooldown - Sahm
Why Catalyst Pharmaceutical (CPRX) is a top value stock for the long term - MSN
CPRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock? - Yahoo Finance
Is Catalyst Pharmaceuticals Inc likely to announce a buyback2026 Risk Factors & Daily Volume Surge Signals - baoquankhu1.vn
Market Wrap: Is Catalyst Pharmaceuticals Inc likely to announce a buyback2026 Weekly Recap & Weekly Watchlist of Top Performers - baoquankhu1.vn
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Patent trial on Catalyst (NASDAQ: CPRX) FIRDAPSE® patents delayed to May 18, 2026 - Stock Titan
Catalyst Pharmaceuticals, Inc. Files Form 8-K with SEC Detailing Company Information and Stock Listing on NASDAQ - Minichart
Catalyst Pharma Patent Trial Against Hetero USA Delayed - TipRanks
Catalyst Pharmaceuticals IncDistrict court delays bench trial to May 18, 2026SEC filing - marketscreener.com
Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals (NASDAQ: CPRX) FIRDAPSE patent trial pushed to May 2026 - Stock Titan
Catalyst Pharmaceuticals (CPRX) reports record Q4 and full year 2025 results - MSN
Catalyst Pharmaceuticals, Inc. (CPRX): A bull case theory - MSN
Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why - TradingView
Analyst Upgrade: Is Catalyst Pharmaceuticals Inc a defensive stock2026 Macro Moves & Scalable Portfolio Growth Methods - baoquankhu1.vn
CPRX Stock Price, Quote & Chart | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
(CPRX) Risk Channels and Responsive Allocation - Stock Traders Daily
Aug Rallies: Should I trade or invest in Catalyst Pharmaceuticals IncOptions Play & Community Verified Trade Signals - baoquankhu1.vn
Merger Talk: Does Catalyst Pharmaceuticals Inc align with a passive investing strategy2026 Macro Moves & Weekly Setup with High ROI Potential - baoquankhu1.vn
A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Softness - Yahoo Finance
Is Catalyst Pharmaceuticals (CPRX) Pricing Reflect Long Term Value After Rare Disease Interest? - Yahoo Finance
Here's why Catalyst Pharmaceutical (CPRX) is a strong value stock - MSN
Is Catalyst Pharmaceuticals (CPRX) Offering Value After Strong Multi‑Year Share Price Gains - simplywall.st
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Weakness - Sahm
Catalyst Pharmaceuticals Touts Firdapse Growth, Agamree Traction as Fycompa Faces Generics - MarketBeat
Fundsmith LLP Acquires 654,721 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
United Therapeutics Stock Surges 32% in 6 Months: Here's Why - TradingView
Kennedy Capital Management LLC Grows Position in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
EPS Watch: Is Catalyst Pharmaceuticals Inc a defensive stockAnalyst Downgrade & Entry Point Confirmation Alerts - baoquankhu1.vn
2025 results exceed expectations as 2026 outlook set, Catalyst Pharmaceuticals projects - Traders Union
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It? - TradingView
Catalyst Pharmaceuticals, Inc. $CPRX Shares Sold by Fieldview Capital Management LLC - MarketBeat
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Presents a Compelling Value Investment Case - ChartMill
Catalyst Pharmaceuticals: Exceptional Fundamentals Trading at 20-33% Discount - Investing.com
Zacks.com featured highlights include Air Lease, National Energy, Catalyst and JBT Marel - The Globe and Mail
Catalyst Pharmaceuticals at Barclays Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
Geopolitical Volatility Boosts Value Investing: 4 Low-PEG Picks - TradingView
Catalyst Pharmaceuticals: Exceptional Fundamentals Trading at 20-33% Discount - TradingView
BMY Advances CELMoD Program With Positive Phase III Results - TradingView
Neo Ivy Capital Management Sells 104,411 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Intech Investment Management LLC Sells 46,656 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Why Catalyst Pharmaceuticals (CPRX) Is Up 5.0% After Raising Its 2026 Revenue Outlook And What’s Next - Sahm
Operating margin % of Catalyst Pharmaceuticals, Inc. – HAM:CN2 - TradingView
(CPRX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
How Much Upside is Left in Catalyst (CPRX)? Wall Street Analysts Think 43.34% - Finviz
Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference - The Manila Times
Catalyst Pharmaceuticals to Present Real-World Findings on Duchenne Muscular Dystrophy at 2026 MDA Conference - Quiver Quantitative
1.82%
자본화:
|
볼륨(24시간):